[Hepatotoxicity of antimitotic treatments. Effect of hepatic tests].
D000293:Adolescent; D000328:Adult; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D002699:Chlorambucil / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D015122:Mercaptopurine / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D008875:Middle Aged; D008937:Mitomycins / Q000009:adverse effects; D009369:Neoplasms / Q000188:drug therapy; D051381:Rats; D014520:Urethane / Q000009:adverse effects; D014747:Vinblastine / Q000009:adverse effects; D014750:Vincristine / Q000009:adverse effects
D000970:Antineoplastic Agents; D008937:Mitomycins; D002699:Chlorambucil; D014520:Urethane; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D008727:Methotrexate
Hépatotoxicité des traitements antimitotiques. Effet sur les tests hépatiques.